Cornerstone Capital, Inc. Viking Therapeutics, Inc. Transaction History
Cornerstone Capital, Inc.
- $988 Million
- Q2 2024
A detailed history of Cornerstone Capital, Inc. transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Cornerstone Capital, Inc. holds 33,950 shares of VKTX stock, worth $2.21 Million. This represents 0.18% of its overall portfolio holdings.
Number of Shares
33,950
Previous 33,950
-0.0%
Holding current value
$2.21 Million
Previous $2.78 Million
35.36%
% of portfolio
0.18%
Previous 0.29%
Shares
23 transactions
Others Institutions Holding VKTX
# of Institutions
443Shares Held
63.4MCall Options Held
6.23MPut Options Held
2.97M-
Vanguard Group Inc Valley Forge, PA10.1MShares$656 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$391 Million0.01% of portfolio
-
State Street Corp Boston, MA5.12MShares$333 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.25MShares$146 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA1.86MShares$121 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $4.98B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...